These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 27003143)

  • 1. Novel Pharmacotherapy Options for NASH.
    Ratziu V
    Dig Dis Sci; 2016 May; 61(5):1398-405. PubMed ID: 27003143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for Nonalcoholic Fatty Liver Disease.
    Gawrieh S; Chalasani N
    Semin Liver Dis; 2015 Aug; 35(3):338-48. PubMed ID: 26378648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review.
    Guirguis E; Grace Y; Bolson A; DellaVecchia MJ; Ruble M
    Pharmacotherapy; 2021 Mar; 41(3):315-328. PubMed ID: 33278029
    [TBL] [Abstract][Full Text] [Related]  

  • 5.  NASH: A glance at the landscape of pharmacological treatment.
    Brodosi L; Marchignoli F; Petroni ML; Marchesini G
    Ann Hepatol; 2016; 15(5):673-81. PubMed ID: 27493105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for nonalcoholic steatohepatitis - a safety evaluation.
    Issa D; Wattacheril J; Sanyal AJ
    Expert Opin Drug Saf; 2017 Aug; 16(8):903-913. PubMed ID: 28641031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Rotman Y; Sanyal AJ
    Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of drugs for nonalcoholic steatohepatitis.
    Shen B; Lu LG
    J Dig Dis; 2021 Feb; 22(2):72-82. PubMed ID: 33385317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.
    Eshraghian A
    World J Gastroenterol; 2017 Nov; 23(42):7495-7504. PubMed ID: 29204050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future pharmacological therapies for NAFLD/NASH.
    Sumida Y; Yoneda M
    J Gastroenterol; 2018 Mar; 53(3):362-376. PubMed ID: 29247356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming.
    Jeong SW
    Diabetes Metab J; 2020 Oct; 44(5):640-657. PubMed ID: 33115209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.
    Filozof C; Goldstein BJ; Williams RN; Sanyal A
    Drugs; 2015 Aug; 75(12):1373-92. PubMed ID: 26201461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.
    Alkhouri N
    Expert Opin Investig Drugs; 2020 Feb; 29(2):87. PubMed ID: 31984804
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Gawrieh S; Chalasani N
    Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?].
    Huber Y; Galle PR; Schattenberg JM
    Z Gastroenterol; 2020 Jan; 58(1):68-73. PubMed ID: 31931543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
    Venetsanaki V; Karabouta Z; Polyzos SA
    Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H; Dufour JF
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.
    Fraile JM; Palliyil S; Barelle C; Porter AJ; Kovaleva M
    Drug Des Devel Ther; 2021; 15():3997-4009. PubMed ID: 34588764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.